ReviewBreathe (Sheffield, England)2026
Spatiotemporal immune dynamics in lung cancer progression and treatment.
Review in Breathe (Sheffield, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Macrophages in lung cancer: principal factors, regulatory mechanisms, and therapeutic opportunities: a narrative review.Translational lung cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lung tumour microenvironment is a complex and evolving ecosystem in which immune, stromal and malignant cells interact across both space and time. Spatial organisation determines whether immune cells can access and induce immune responses across tumour tissues, while temporal changes driven by disease progression and therapy reshape these interactions. Although advances in high-plex technologies have revealed discrete immune niches in lung cancer, particularly in nonsmall cell lung carcinoma (NSCLC), less is known about how these tissue landscape niches remodel over time. This review integrates spatial and temporal perspectives to provide a unified view of lung cancer immunobiology. We discuss how fibroblast activation, endothelial remodelling and extracellular matrix deposition restrict immune infiltration and how conventional therapies and targeted inhibitors can remodel these barriers. We highlight recent studies that reveal how immune functional states shift with treatment and cancer stages. Finally, we outline how emerging technologies (spatial transcriptomics, multiplex imaging and functional assays) offer new opportunities to link temporal transitions with spatial immune context. Understanding spatiotemporal dynamics will be key to stage-specific biomarker discovery, treatment optimisation and personalised strategies in NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.